Additionally, another study has examined the effects of a novel sulfonimide derivative 4 with PPAR-α antagonistic feature and a weaker PPAR-γ antagonism, and the novel compound potently impairs the viability of pancreatic cancer cell lines, indicating an inhibition of PPAR-α and PPAR-γ could be a therapeutic option for pancreatic cancer (52). The gene discussed is PPARA; the disease is pancreatic neoplasm.